Treatment planning and dosimetry for the Harvard-MIT Phase I clinical trial of cranial neutron capture therapy

A Phase I trial of cranial neutron capture therapy (NCT) was conducted at Harvard-MIT. The trial was designed to determine maximum tolerated NCT radiation dose to normal brain. Twenty-two patients with brain tumors were treated by infusion of boronophenylalanine-fructose (BPA-f) followed by exposure...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of radiation oncology, biology, physics Vol. 53; no. 5; p. 1361
Main Authors:	Palmer, Matthew R, Goorley, J Timothy, Kiger, W S, Busse, Paul M, Riley, Kent J, Harling, Otto K, Zamenhof, Robert G
Format:	Journal Article
Language:	English
Published:	United States 01-08-2002
Subjects:	Adult Aged Boron - blood Brain - radiation effects Brain Neoplasms - radiotherapy Female Glioblastoma - radiotherapy Humans Male Melanoma - radiotherapy Middle Aged Neutron Capture Therapy - methods Neutrons Phantoms, Imaging Radiometry - methods Radiotherapy Planning, Computer-Assisted - methods Tomography, X-Ray Computed
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A Phase I trial of cranial neutron capture therapy (NCT) was conducted at Harvard-MIT. The trial was designed to determine maximum tolerated NCT radiation dose to normal brain. Twenty-two patients with brain tumors were treated by infusion of boronophenylalanine-fructose (BPA-f) followed by exposure to epithermal neutrons. The study began with a prescribed biologically weighted dose of 8.8 RBE (relative biologic effectiveness) Gy, escalated in compounding 10% increments, and ended at 14.2 RBE Gy. BPA-f was infused at a dose 250-350 mg/kg body weight. Treatments were planned using MacNCTPlan and MCNP 4B. Irradiations were delivered as one, two, or three fields in one or two fractions. Peak biologically weighted normal tissue dose ranged from 8.7 to 16.4 RBE Gy. The average dose to brain ranged from 2.7 to 7.4 RBE Gy. Average tumor dose was estimated to range from 14.5 to 43.9 RBE Gy, with a mean of 25.7 RBE Gy. We have demonstrated that BPA-f-mediated NCT can be precisely planned and delivered in a carefully controlled manner. Subsequent clinical trials of boron neutron capture therapy at Harvard and MIT will be initiated with a new high-intensity, high-quality epithermal neutron beam.
ISSN:	0360-3016
DOI:	10.1016/S0360-3016(02)02862-6